[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 50.16.125.253. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
On the Horizon
November 17, 2008

Cytokine Milieu in Psoriasis and Cardiovascular Disease May Explain the Epidemiological Findings Relating These 2 Diseases

Author Affiliations
 

CRAIG A.ELMETSMDMOLLY A.HINSHAWMDJAY C.KLEMMEMD, MPHMARK R.PITTELKOWMDMARIA L. CHANCOTURNERMDMARTIN A.WEINSTOCKMD, PhDDAVID T.WOODLEYMD

Arch Dermatol. 2008;144(11):1518-1519. doi:10.1001/archderm.144.11.1518

Interleukin-12, Interleukin-23, and Psoriasis: Current Prospects Torti DC, Feldman SR J Am Acad Dermatol. 2007;57(6):1059-1068

The clinical phenotype of psoriasis results from infiltration of T cells in the skin and elaboration of inflammatory cytokines. Interleukin (IL)-12 and, more recently, IL-23 have been implicated in the pathogenesis of psoriatic lesions. New therapies, including a monoclonal antibody against a subunit shared by IL-12 and IL-23, have been developed to treat psoriasis. Our purpose was to review the literature on IL-12 and IL-23 as a basis for understanding the use of anti-IL-12/IL-23 therapy for psoriasis. A review of English-language articles was performed using PubMed to identify articles pertaining to IL-12, IL-23, and psoriasis. IL-12 and IL-23 share a common subunit (p40) and have a distinct subunit (p35 and p19, respectively). Transgenic mice that overexpress IL-12 p40 develop inflammatory skin lesions. Both IL-12 knockout mice, which are deficient in IL-12, and human beings with a genetic IL-12 deficiency show increased susceptibility to intracellular pathogens and defective delayed-type hypersensitivity responses. These genetic deficiency states suggest the potential for adverse side effects from clinical administration of anti IL-12 p40 therapy. IL-12 p40 antibody was well tolerated in a phase I clinical trial with few adverse events and substantial improvements in psoriasis in most individuals. There was dose-dependent efficacy and substantial improvement in a larger cohort of patients in a phase II clinical trial. Larger and longer trials of anti IL-12/IL-23 therapies are needed to assess their clinical use and potential for infection and other adverse events.

First Page Preview View Large
First page PDF preview
First page PDF preview
×